

Unless otherwise defined in this announcement, terms defined in the prospectus of Jacobson Pharma Corporation Limited (the “Company”) dated 8 September 2016 (the “Prospectus”) have the same meanings when used in this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not an offer of securities for sale in the United States. The securities described herein have not, and will not, be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or with any securities regulatory authority of any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in the United States unless the securities are so registered or an exemption from the registration requirements is available. The Hong Kong Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. There will not and is not currently intended to be any public offering of securities in the United States. Any public offering of securities in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as its financial statements.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited
雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on 13 October 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by BOCI Asia Limited, the Stabilizing Manager, during the stabilization period were:

- (1) over-allocations of an aggregate of 65,625,000 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);

- (2) borrowing of 65,625,000 Shares by the Stabilizing Manager from Kingshill to cover over-allocations in the International Offering; and
- (3) the full exercise of the Over-allotment Option by the Sole Global Coordinator on behalf of the International Underwriters on 3 October 2016 (after trading hours) in respect of 65,625,000 additional new Shares, representing 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at the Offer Price per Share, to facilitate the return to Kingshill of the 65,625,000 borrowed Shares which were used to cover over-allocations in the International Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company makes this announcement pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and announces that the stabilization period in connection with the Global Offering ended on 13 October 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by BOCI Asia Limited, the Stabilizing Manager, during the stabilization period involved:

- (1) over-allocations of an aggregate of 65,625,000 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) borrowing of 65,625,000 Shares by the Stabilizing Manager from Kingshill to cover over-allocations in the International Offering; and
- (3) the full exercise of the Over-allotment Option by the Sole Global Coordinator on behalf of the International Underwriters on 3 October 2016 (after trading hours) in respect of 65,625,000 additional new Shares, representing 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at the Offer Price per Share, to facilitate the return to Kingshill of the 65,625,000 borrowed Shares which were used to cover over-allocations in the International Offering.

For further details in relation to the full exercise of the Over-allotment Option, please refer to the announcement of the Company dated 3 October 2016. The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Hong Kong Listing Rules.

By order of the Board
Jacobson Pharma Corporation Limited
Wong Wai Ming
Company Secretary

Hong Kong, 13 October 2016

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chief Executive Officer), Mr. Lo Chun Bun and Mr. Yim Chun Leung as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Professor Chow Hee Lum, Albert, Dr. Lam Kwing Tong, Alan and Mr. Young Chun Man, Kenneth as independent non-executive Directors.